Breaking News

Vetter Affirms Strategic Commitment to Sustainability

Earns EcoVadis Platinum Rating and validation of its emission reduction targets by the Science Based Targets initiative (SBTi).

Author Image

By: Charlie Sternberg

Associate Editor

Local biomethane powers Vetter’s sites, uniting climate protection and regional value. Image courtesy of Naturenergie Rotachtal GmbH & Co. KG.

Vetter, a Contract Development and Manufacturing Organization (CDMO), has earned an EcoVadis Platinum rating and received validation of its emission reduction targets by the Science Based Targets initiative (SBTi). Both achievements highlight the company’s commitment to climate protection and responsible business practices.

This is the fourth consecutive year that Vetter has been recognized by the EcoVadis sustainability ranking, earning Platinum status for 2025 and placing itself among the top 1 percent of all rated companies globally.

The official validation of the emission reduction targets by the SBTi approves Vetter’s ambitious sustainability roadmap: by 2034, the CDMO aims to reduce absolute greenhouse gas emissions from Scope 1 and 2 by 58.8 percent (baseline 2021). These goals align with the Paris Agreement and represent one of the most rigorous standards for corporate climate action worldwide. The planned reductions will be achieved through a comprehensive mix of measures, including technical modernization of facilities and equipment, leveraging energy recovery potentials such as waste heat, and transitioning to lower-carbon energy sources–for example, replacing natural gas with biomethane.

“We are proud of the various steps we are taking to reduce our company’s carbon footprint,” said Managing Director Henryk Badack. “Both the validation by the SBTi and the Platinum rating from EcoVadis emphasize our strategic commitment to both people and planet and bring us one step closer to effective climate protection and to achieving overall sustainabilty goals.”

More Vetter News

In June, Vetter began construction of its new clinical manufacturing site in Des Plaines.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters